Viatris Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 32/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 12.46.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Viatris Inc's Score
Industry at a Glance
Industry Ranking
32 / 158
Overall Ranking
85 / 4582
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
12
analysts
Hold
Current Rating
12.457
Target Price
+12.32%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Viatris Inc Highlights
StrengthsRisks
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -3.81, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 987.12M shares, decreasing 4.49% quarter-over-quarter.
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
Ticker SymbolVTRS
CompanyViatris Inc
CEOSmith (Scott A)
Websitehttps://www.viatris.com/en
FAQs
What is the current price of Viatris Inc (VTRS)?
The current price of Viatris Inc (VTRS) is 11.930.
What is the symbol of Viatris Inc?
The ticker symbol of Viatris Inc is VTRS.
What is the 52-week high of Viatris Inc?
The 52-week high of Viatris Inc is 12.680.
What is the 52-week low of Viatris Inc?
The 52-week low of Viatris Inc is 6.850.
What is the market capitalization of Viatris Inc?
The market capitalization of Viatris Inc is 13.83B.
What is the net income of Viatris Inc?
The net income of Viatris Inc is -634.20M.
Is Viatris Inc (VTRS) currently rated as Buy, Hold, or Sell?
According to analysts, Viatris Inc (VTRS) has an overall rating of Hold, with a price target of 12.457.
What is the Earnings Per Share (EPS TTM) of Viatris Inc (VTRS)?
The Earnings Per Share (EPS TTM) of Viatris Inc (VTRS) is -3.131.